Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial

BACKGROUND: We evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants. METHODS: This phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Taisei, Murakami, Kyoko, Sugiura, Kenkichi, Sakui, Sho, Schuring, Ron P, Mori, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053833/
https://www.ncbi.nlm.nih.gov/pubmed/35501178
http://dx.doi.org/10.1016/j.vaccine.2022.04.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053833/
https://www.ncbi.nlm.nih.gov/pubmed/35501178
http://dx.doi.org/10.1016/j.vaccine.2022.04.035

Ejemplares similares